6th Obesity and NASH Drug Development Summit 2022
Evvnt Promotion / evvnt
Archivo
29.11.2022 - 01.12.2022 Revere Hotel Boston Common, 200 Stuart Street, 02116 Boston, Massachusetts, USA
Time: 09:55 - 16:40
Temas de la conferencia
The first wave of investment in NASH is dispersing in the wake of highly demanding biopsy endpoints, but opportunities to target obesity and metabolic syndrome are catalyzing increasing excitement. Pivotal readouts in GLP-1 receptor agonists and exciting progress in regenerative medicine and microRNAs are redefining the drug development landscape for metabolic disorders.
The first wave of investment in NASH is dispersing in the wake of highly demanding biopsy endpoints, but opportunities to target obesity and metabolic syndrome are catalyzing increasing excitement. Pivotal readouts in GLP-1 receptor agonists and exciting progress in regenerative medicine and microRNAs are redefining the drug development landscape for metabolic disorders.
Organizador profesional (PCO)
Hanson Wade
Hanson Wade
Observaciones
Brochure: https://go.evvnt.com/1277295-3?pid=4832
Speakers: Allison Goldfine, Director, Translational Medicine Cardiometabolic Disease, Novartis, Andrew Billin, Senior Director Biomarker Sciences, Gilead, and more.
Brochure: https://go.evvnt.com/1277295-3?pid=4832
Speakers: Allison Goldfine, Director, Translational Medicine Cardiometabolic Disease, Novartis, Andrew Billin, Senior Director Biomarker Sciences, Gilead, and more.
Información e inscripción:
https://go.evvnt.com/1277295-2?pid=4832
Ms. Jessica Durston
Medicina General
Cantacto organizador
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International fomenta el acceso a la educación y a la formación continua independientemente de fronteras sociales, geográficas y nacionales."
